基于树突状细胞的肿瘤免疫治疗临床应用方式的研究进展

沈季敏; 刘欣

doi:10.13201/j.issn.1004-2806.2018.01.016

基于树突状细胞的肿瘤免疫治疗临床应用方式的研究进展

沈季敏,
刘欣^,

- 安徽医科大学附属省立医院, 安徽省立医院血液科(合肥, 230001)
基金项目:
安徽省自然科学基金项目(No:1508085MH195)

详细信息

通讯作者: 刘欣,E-mail:lxinahf@sina.com

中图分类号: R730.51

收稿日期: 2017-04-20

Research progress in clinical application of tumor immune therapy based on dendritic cells

SHEN Jimin,
LIU Xin^,

More Information

Corresponding author: LIU Xin, E-mail: lxinahf@sina.com

Received Date: 20 April 2017

摘要

- 树突状细胞 /
- 肿瘤 /
- 免疫治疗
Abstract: Dendritic cells (DCs) are professional antigen-presenting cells which play a key role in both immunity induction and tolerance maintenance.DC is the strongest and the only one antigen presenting cell which can directly activate the initial T cells in vivo,initiating the adaptive immune response.In this paper,we discuss the new understanding of DC-based tumor immunotherapy,and the clinical studies of DCs that have been carried out so far in combination with other therapies.
- dendritic cells /
- tumor /
- immunotherapy

HTML全文

参考文献(25)

[1]	Chen D, Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity, 2013, 9:1-10.
[2]	Mildner A, Jung S.Development and function of dendritic cell subsets[J].Immunity, 2014, 40:642-656.
[3]	郭振红, 曹雪涛.肿瘤免疫细胞治疗的现状及展望[J].中国肿瘤生物治疗杂志, 2016, 23 (2):149-160.
[4]	Lim S, Koo JH, Choi JM.Use of cell-penetrating peptides in dendritic cell-based vaccination[J].Immune Netw, 2016, 16:33-43.
[5]	Hoos A, Wolchok JD, Humphrey RW, et al.CCR 20th anniversary commentary:immune-related response criteria-capturing clinical activity in immuno-oncology[J].Clin Cancer Res, 2015, 21:4989-4991.
[6]	Guo L, Zhang H, Chen B.Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor[J].J Cancer, 2017, 8:410-416.
[7]	Wilgenhof S, Corthals J, Heirman C, et al.Phase IIstudy of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma[J].J Clin Oncol, 2016, 34:1330-1338.
[8]	Lanitis E, Irving M, Coukos G.Targeting the tumor vasculature to enhance T cell activity[J].Curr Opin Immunol, 2015, 33:55-63.
[9]	Wesolowski R, Markowitz J, Carson WE.Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer[J].J Immunother Cancer, 2013, 1:10.
[10]	Prendergast GC, Smith C, Thomas S, et al.Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer[J].Cancer Immunol Immunother, 2014, 63:721-735.
[11]	Ursu R, Taillibert S, Banissi C, et al.Immunotherapy with CpG-ODN in neoplastic meningitis:A phase I trial[J].Cancer Sci, 2015, 106:1212-1218.
[12]	Ilieva KM, Correa I, Josephs DH, et al.Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma[J].Mel Cancer Ther, 2014, 13:2769-2783.
[13]	Amin A, Dudek AZ, Logan TF, et al.Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC):Phase 2study results[J].J Immunother Cancer, 2015, 3:14.
[14]	Jung NC, Lee JH, Choi HJ, et al.Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice[J].Immunol Invest, 2016, 45:553-565.
[15]	Mao Q, Li L, Zhang C, et al.Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer[J].Pak J Pharm Sci, 2015, 28:1055-1058.
[16]	Wang D, Zhang B, Gao H, et al.Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer[J].BMC Cancer, 2014, 14:251.
[17]	Rosalia RA, Quakkelaar ED, Redeker A, et al.Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation[J].Eur J Immunol, 2013, 43:2554-2565.
[18]	Aspord C, Leloup C, Reche S, et al.pDCs efficiently process synthetic long peptides to induce functional virus-and tumour-specific T-cell responses[J].Eur J Immunol, 2014, 44:2880-2892.
[19]	Fukuda K, Funakoshi T, Sakurai T.Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma[J].Melanoma Res, 2017, 27:326-334.
[20]	Shigetaka S, Kenji S, Koichi H, et al.Dendritic cellbased adjuvant vaccination targeting Wilms'tumor 1in patients with advanced colorectal cancer[J].Vaccines, 2015, 3:1004-1018.
[21]	Fonteneau JF, Brilot F, Münz C, et al.The tumor antigen NY-ESO-1mediates direct recognition of melanoma cells by CD4+T cells after intercellular antigen transfer[J].J Immunol, 2016, 196:64-71.
[22]	Fracol M, Xu S, Mick R, et al.Response to HER-2pulsed DC1vaccines is predicted by both HER-2and estrogen receptor expression in DCIS[J].Ann Surg Oncol, 2013, 20:3233.
[23]	Liu S, Yi L, Ling M, et al.HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer[J].Cell Mol Immunol, 2016Jun 27.doi:10.1038/cmi.2016.33.[Epub ahead of print].
[24]	Rosenberg SA, Restifo NP.Adoptive cell transfer as personalized immunotherapy for human cancer[J].Science, 2015, 348:62-68.
[25]	Wang C, Pu J, Yu H, et al.A dendritic cell vaccine combined with radiotherapy activates the specific immune response in patients with esophageal cancer[J].J Immunother, 2017, 40:71-76.